The DOI matches its Crossref record; 348 of the 353 references it cites were found in a registry or an index.
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Open accessAbstract
γ-aminobutyric acid (GABA) is the primary inhibitory neurotransmitter in the vertebrate brain. In the past, there has been a major research drive focused on the dysfunction of the glutamatergic and cholinergic neurotransmitter systems in Alzheimer’s disease (AD). However, there is now growing evidence in support of a GABAergic contribution to the pathogenesis of this neurodegenerative disease. Previous studies paint a complex, convoluted and often inconsistent picture of AD-associated GABAergic remodeling. Given the importance of the GABAergic system in neuronal function and homeostasis, in the maintenance of the excitatory/inhibitory balance, and in the processes of learning and memory, such changes in GABAergic function could be an important factor in both early and later stages of AD pathogenesis. Given the limited scope of currently available therapies in modifying the course of the disease, a better understanding of GABAergic remodeling in AD could open up innovative and novel therapeutic opportunities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Loss of GABA, the primary inhibitory neurotransmitter in the brain, is a key component of AD.”
From Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease (2019) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
2013 Alzheimer's disease facts and figures
Thies, W. H., & Bleiler, L. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.02.003 · Cited by 3,372
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Excitatory actions of gaba during development: the nature of the nurture
Ben-Ari, Y. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn920 · Cited by 2,448
Cortical inhibitory neurons and schizophrenia
Lewis, D. A., Hashimoto, T., & Volk, D. W. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1648 · Cited by 2,297
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
New neurons and new memories: how does adult hippocampal neurogenesis affect learning and memory?
Deng, W., Aimone, J. B., & Gage, F. H. (2010) · Nature reviews. Neuroscience · doi:10.1038/nrn2822 · Cited by 2,120
Flagged first, then by citations
5 of the 353 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Wyper, 1998, Single photon emission computed tomography in Alzheimer’s disease: Cerebral perfusion and acetylcholine muscarinic receptor imaging and a novel study of the GABA/benzodiazepine system, Int. J. Geriatr. Psychopharmacol., 1, 126
Cited by
Sorted by citations
Dominy, S. S., Lynch, C., Ermini, F., Benedyk, M., Marczyk, A., Konradi, A., Nguyen, M., Haditsch, U., Raha, D., Griffin, C., et al. (2019) · Science Advances · doi:10.1126/sciadv.aau3333 · Cited by 1,966
Self-citationPathological mechanisms and therapeutic strategies for Alzheimer’s disease
Tam, K. Y., & Ju, Y. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320970 · Cited by 422
Influence of glutamate and GABA transport on brain excitatory/inhibitory balance
Sears, S. M. S., & Hewett, S. J. (2021) · Experimental Biology and Medicine · doi:10.1177/1535370221989263 · Cited by 371
Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons
Ruan, Z., Pathak, D., Venkatesan Kalavai, S., Yoshii-Kitahara, A., Muraoka, S., Bhatt, N., Takamatsu-Yukawa, K., Hu, J., Wang, Y., Hersh, S., et al. (2021) · Brain · doi:10.1093/brain/awaa376 · Cited by 283
Govindpani, K., McNamara, L. G., Smith, N. R., Vinnakota, C., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8050651 · Cited by 281
Self-citationBi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
Zhuang, Z., Yang, R., Wang, W., Qi, L., & Huang, T. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-01961-8 · Cited by 220
GABAergic Inhibitory Interneuron Deficits in Alzheimer’s Disease: Implications for Treatment
Xu, Y., Zhao, M., Han, Y., & Zhang, H. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00660 · Cited by 203
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Glutamate and GABA in Microglia-Neuron Cross-Talk in Alzheimer’s Disease
Czapski, G. A., & Strosznajder, J. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111677 · Cited by 198
Jiménez-Baladó, J., & Eich, T. S. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.01.005 · Cited by 194
Neural oscillations and brain stimulation in Alzheimer’s disease
Jafari, Z., Kolb, B. E., & Mohajerani, M. H. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101878 · Cited by 192
The GABAergic system as a therapeutic target for Alzheimer's disease
Guzmán, B. C., Vinnakota, C., Govindpani, K., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14345 · Cited by 172
Self-citationLauterborn, J. C., Scaduto, P., Cox, C. D., Schulmann, A., LYNCH, G. S., Gall, C. M., Keene, C. D., & Limón, A. (2021) · Nature Communications · doi:10.1038/s41467-021-22742-8 · Cited by 149
Positive allosteric modulation of GABAA receptors by a novel antiepileptic drug cenobamate
Sharma, R., Nakamura, M., Neupane, C., Jeon, B. H., Shin, H., Melnick, S. M., Glenn, K., Jang, I., & Park, J. B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173117 · Cited by 135
The Many Faces of Astrocytes in Alzheimer's Disease
Monterey, M. D., Wei, H., Wu, X., & Wu, J. Q. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.619626 · Cited by 117
Tette, F.-M., Kwofie, S. K., & Wilson, M. D. (2022) · Current Issues in Molecular Biology · doi:10.3390/cimb44040096 · Cited by 119
Dilmore, A. H., Martino, C., Neth, B. J., West, K., Zemlin, J., Rahman, G., Panitchpakdi, M. W., Meehan, M. J., Weldon, K. C., Blach, C., et al. (2023) · Alzheimer s & Dementia · doi:10.1002/alz.13007 · Cited by 108
Unsupervised excitation: GABAergic dysfunctions in Alzheimer’s disease
Giovannetti, E. A., & Fuhrmann, M. (2018) · Brain Research · doi:10.1016/j.brainres.2018.11.042 · Cited by 105
Piras, I. S., Krate, J., Delvaux, E., Nolz, J., Mastroeni, D., Persico, A. M., Jepsen, W. M., Beach, T. G., Huentelman, M. J., & Coleman, P. D. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-181113 · Cited by 100
Kwakowsky, A., Guzmán, B. C., Pandya, M., Turner, C. P., Waldvogel, H. J., & Faull, R. L. M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14325 · Cited by 96
Self-citationThe GABAergic system in Alzheimer’s disease: a systematic review with meta-analysis
Carello-Collar, G., Bellaver, B., Ferreira, P. C. L., Ferrari-Souza, J. P., Ramos, V. G., Therriault, J., Tissot, C., De Bastiani, M. A., Soares, C., Pascoal, T. A., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02140-w · Cited by 98
Learning interpretable cellular and gene signature embeddings from single-cell transcriptomic data
Zhao, Y., Cai, H., Zhang, Z., Tang, J., & Li, Y. (2021) · Nature Communications · doi:10.1038/s41467-021-25534-2 · Cited by 91
Nobukawa, S., Yamanishi, T., Kasakawa, S., Nishimura, H., Kikuchi, M., & Takahashi, T. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00255 · Cited by 89
Sex- and age-related changes in GABA signaling components in the human cortex
Pandya, M., Palpagama, T. H., Turner, C. P., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · Biology of Sex Differences · doi:10.1186/s13293-018-0214-6 · Cited by 89
Self-citationImpaired Expression of GABA Signaling Components in the Alzheimer’s Disease Middle Temporal Gyrus
Govindpani, K., Turner, C. P., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21228704 · Cited by 85
Self-citationβ-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer’s Disease Therapy
Beato, A., Gori, A., Boucherle, B., Peuchmaur, M., & Haudecoeur, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01887 · Cited by 87
Lopatina, O. L., Malinovskaya, N. A., Komleva, Y. K., Gorina, Y. V., Shuvaev, A. N., Olovyannikova, R. Y., Belozor, O. S., Belova, O. A., Higashida, H., & Salmina, A. B. (2019) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0014 · Cited by 74
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
Haghighijoo, Z., Zamani, L., Moosavi, F., & Emami, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113949 · Cited by 77
Nobukawa, S., Yamanishi, T., Nishimura, H., Wada, Y., Kikuchi, M., & Takahashi, T. (2018) · Cognitive Neurodynamics · doi:10.1007/s11571-018-9509-x · Cited by 68
The Effect of Oral GABA on the Nervous System: Potential for Therapeutic Intervention
Almutairi, S., Sivadas, A., & Kwakowsky, A. (2024) · Nutraceuticals · doi:10.3390/nutraceuticals4020015 · Cited by 74
Self-citationThe Role of the Microbiota–Gut–Brain Axis and Antibiotics in ALS and Neurodegenerative Diseases
Obrenovich, M., Jaworski, H., Tadimalla, T., Mistry, A., Sykes, L., Perry, G., & Bonomo, R. (2020) · Microorganisms · doi:10.3390/microorganisms8050784 · Cited by 62
Glia: A major player in glutamate–GABA dysregulation‐mediated neurodegeneration
Sood, A., Kumari, P., Fernandes, V., Khatri, D. K., & Singh, S. B. (2021) · Journal of Neuroscience Research · doi:10.1002/jnr.24977 · Cited by 60
Guzmán, B. C., Chaffey, T. E., Palpagama, T. H., Waters, S., Boix, J., Tate, W. P., Peppercorn, K., Dragunow, M., Waldvogel, H. J., Faull, R. L. M., et al. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.552073 · Cited by 63
Self-citationLam, P., Newland, J., Faull, R. L. M., & Kwakowsky, A. (2023) · Molecules · doi:10.3390/molecules28031344 · Cited by 59
Self-citationPiļipenko, V., Narbute, K., Amara, I., Salinaro, A. T., Scuto, M. C., Pupure, J., Jansone, B., Poikāns, J., Bisenieks, E., Kluša, V., et al. (2019) · Journal of Neuroscience Research · doi:10.1002/jnr.24396 · Cited by 58
Li, H., Cui, X., Lin, Y., Huang, F., Tian, A., & Zhang, R. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1422350 · Cited by 65
Regulation of Melatonin and Neurotransmission in Alzheimer’s Disease
Roy, J., Tsui, K. C., Ng, J., Fung, M., & Lim, L. W. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136841 · Cited by 55
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 59
Bimonte, S., & Cascella, M. (2017) · Neural Regeneration Research · doi:10.4103/1673-5374.219032 · Cited by 55
Xu, H., Zhou, Q., Liu, B., Cheng, K., Chen, F., & Wang, M. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c04049 · Cited by 50
Ando, M., Nobukawa, S., Kikuchi, M., & Takahashi, T. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.667614 · Cited by 48
Synaptosome microRNAs regulate synapse functions in Alzheimer’s disease
Kumar, S., Orlov, E., Gowda, P., Bose, C., Swerdlow, R. H., Lahiri, D. K., & Reddy, P. H. (2022) · npj Genomic Medicine · doi:10.1038/s41525-022-00319-8 · Cited by 46
Morrone, C. D., Lai, A. Y., Bishay, J., Hill, M. E., & McLaurin, J. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00300-6 · Cited by 43
Kwakowsky, A., Guzmán, B. C., Govindpani, K., Waldvogel, H. J., & Faull, R. L. M. (2018) · Neural Regeneration Research · doi:10.4103/1673-5374.235240 · Cited by 45
Self-citationKaur, S., DasGupta, G., & Singh, S. (2019) · Neurophysiology · doi:10.1007/s11062-019-09823-7 · Cited by 45
Metaxas, A., Thygesen, C., Briting, S. R. R., Landau, A. M., Darvesh, S., & Finsen, B. R. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00538 · Cited by 39
Du, X., Shi, Q., Zhao, Y., Xie, Y., Li, X., Liu, Q., Iqbal, J., Zhang, H., Liu, X., & Shen, L. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00549 · Cited by 38
Ethiraj, J., Palpagama, T. H., Turner, C. P., van der Werf, B., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2021) · Scientific Reports · doi:10.1038/s41598-021-00792-8 · Cited by 39
Self-citationAromas Influencing the GABAergic System
Hartley, N., & Mclachlan, C. (2022) · Molecules · doi:10.3390/molecules27082414 · Cited by 38
Piras, I. S., Krate, J., Delvaux, E., Nolz, J., Both, M. D. D., Mastroeni, D., Serrano, G. E., Sue, L. I., Beach, T. G., Coleman, P. D., et al. (2019) · Brain Research · doi:10.1016/j.brainres.2019.06.004 · Cited by 36
Current Progress on Central Cholinergic Receptors as Therapeutic Targets for Alzheimer's Disease
Nagori, K., Pradhan, M., Sharma, M. K., Ajazuddin, M., Badwaik, H. R., & Nakhate, K. T. (2024) · Current Alzheimer Research · doi:10.2174/0115672050306008240321034006 · Cited by 37
The dialog between neurons and microglia in Alzheimer's disease: The neurotransmitters view
Stolero, N., & Frenkel, D. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15262 · Cited by 37
Hydrogel Film-Immobilized Lactobacillus brevis RK03 for γ-Aminobutyric Acid Production
Hsueh, Y., Liaw, W., Kuo, J., Deng, C.-S., & Wu, C.-H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112324 · Cited by 35
Dementia-related psychosis and the potential role for pimavanserin
Cummings, J. L., Devanand, D. P., & Stahl, S. M. (2020) · CNS Spectrums · doi:10.1017/s1092852920001765 · Cited by 35
Current and Emerging Pharmacological Targets for the Treatment of Alzheimer’s Disease
Morsy, A., & Trippier, P. C. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190744 · Cited by 36
The hippocampus associated GABAergic neural network impairment in early-stage of Alzheimer's disease
Tang, Y., Yan, Y., Mao, J., Ni, J., & Qing, H. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.101865 · Cited by 34
He, Y., Xu, D., Yan, Z., Wu, Y., Zhang, Y., Tian, X., Zhu, J., Liu, Z., Cheng, W., Zheng, K., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1043572 · Cited by 34
Pesch, B., Casjens, S., Woitalla, D., Dharmadhikari, S., Edmondson, D. A., Zella, M. A. S., Lehnert, M., Lotz, A., Herrmann, L., Muhlack, S., et al. (2019) · Cells · doi:10.3390/cells8020096 · Cited by 33
Karimani, A., Ramezani, N., Goli, A. A., Shirazi, M. H. N., Nourani, H., & Jafari, A. M. (2021) · Toxicology Reports · doi:10.1016/j.toxrep.2021.06.017 · Cited by 33
GABA A Receptors Are Well Preserved in the Hippocampus of Aged Mice
Palpagama, T. H., Sagniez, M., Kim, S., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2019) · eNeuro · doi:10.1523/eneuro.0496-18.2019 · Cited by 35
Self-citationZhao, Y., Chen, H., Iqbal, J., Liu, X., Zhang, H., Xiao, S., Jin, N., Yao, F., & Shen, L. (2020) · Journal of Neuroscience Research · doi:10.1002/jnr.24750 · Cited by 32
Zeng, L., Zhang, D., Liu, Q., Zhang, J., Mu, K., Gao, X., Zhang, K., Li, H., Wang, Q., Zheng, Y., et al. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2020.12.026 · Cited by 33
Family C G-Protein-Coupled Receptors in Alzheimer’s Disease and Therapeutic Implications
Prà, I. D., Armato, U., & Chiarini, A. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01282 · Cited by 31
GABA levels decline with age: A longitudinal study
Zuppichini, M. D., Hamlin, A. M., Zhou, Q., Kim, E., Rajagopal, S., Beltz, A. M., & Polk, T. A. (2024) · Imaging Neuroscience · doi:10.1162/imag_a_00224 · Cited by 31
Pasieka, A., Panek, D., Jończyk, J., Godyń, J., Szałaj, N., Latacz, G., Tabor, J., Mezeiová, E., Chantegreil, F., Dias, J., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113397 · Cited by 30
Kong, Y., Huang, L., Li, W., Liu, X., Zhou, Y., Liu, C., Zhang, S., Xie, F., Zhang, Z., Jiang, D., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.609908 · Cited by 29
Guzmán, B. C., Kim, S., Chawdhary, B., Peppercorn, K., Tate, W. P., Waldvogel, H. J., Faull, R. L. M., Montgomery, J. M., & Kwakowsky, A. (2020) · Molecules · doi:10.3390/molecules25030693 · Cited by 27
Self-citationCasani-Cubel, J., Benlloch, M., Sanchis-Sanchis, C. E., Marín, R., Lajara-Romance, J. M., & Ortí, J. E. D. L. R. (2021) · Metabolites · doi:10.3390/metabo11020120 · Cited by 31
Jia, Y., Wang, X., Chen, Y., Qiu, W., Ge, W., & Ma, C. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02356-3 · Cited by 24
Basal forebrain metabolism in Alzheimer's disease continuum: relationship with education
Nicolas, B., Dodich, A., Perani, D., Osman, R., Trombella, S., Frisoni, G. B., & Garibotto, V. (2019) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.11.013 · Cited by 23
Subject-specific features of excitation/inhibition profiles in neurodegenerative diseases
Monteverdi, A., Palesi, F., Costa, A. C., Vitali, P., Pichiecchio, A., Ramusino, M. C., Bernini, S., Jirsa, V., Wheeler‐Kingshott, C. A. M. G., & D'Angelo, E. U. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.868342 · Cited by 23
Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer's disease
Salazar, A., Osse, A. M. L., Ortiz, A. A., Murtishaw, A. S., & Kinney, J. W. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.013 · Cited by 26
Kiss, É., Kins, S., Zöller, Y., Schilling, S., Gorgas, K., Groß, D., Schlicksupp, A., Rosner, R., Kirsch, J., & Kuhse, J. (2021) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2021.103624 · Cited by 22
Sex differences of brain and their implications for personalized therapy
Rezzani, R., Franco, C., & Rodella, L. F. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.01.030 · Cited by 24
Targeting GABAAR-Associated Proteins: New Modulators, Labels and Concepts
Khayenko, V., & Maric, H. M. (2019) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00162 · Cited by 21
Prefrontal GABA Levels Correlate with Memory in Older Adults at High Risk for Alzheimer’s Disease
Murari, G., Liang, D. R.-S., Ali, A., Chan, F., Mulder-Heijstra, M., Verhoeff, N. P. L. G., Herrmann, N., Chen, J. J., & Mah, L. (2020) · Cerebral Cortex Communications · doi:10.1093/texcom/tgaa022 · Cited by 21
Alzheimer’s disease is an inherent, natural part of human brain aging: an integrated perspective
Ferrer, I. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3806 · Cited by 24
Mouro, F. M., Miranda‐Lourenço, C., Sebastião, A. M., & Diógenes, M. J. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00680 · Cited by 22
Rubin, B. R., Milner, T. A., Pickel, V. M., Coleman, C. G., Marques-Lopes, J., Kempen, T. A. V., Kazim, S. F., McEwen, B. S., Gray, J. D., & Pereira, A. C. (2019) · Experimental Neurology · doi:10.1016/j.expneurol.2019.113075 · Cited by 19
Kuhlemann, A., Beliu, G., Janzen, D., Petrini, E. M., Taban, D., Helmerich, D. A., Doose, S., Bruno, M., Barberis, A., Villmann, C., et al. (2021) · Frontiers in Synaptic Neuroscience · doi:10.3389/fnsyn.2021.727406 · Cited by 20
CSF metabolites associated with biomarkers of Alzheimer’s disease pathology
Dong, R., Lu, Q., Kang, H., Suridjan, I., Kollmorgen, G., Wild, N., Deming, Y. K., Hulle, C. A. V., Anderson, R. M., Zetterberg, H., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1214932 · Cited by 24
Neurotransmitter imbalance dysregulates brain dynamic fluidity in frontotemporal degeneration
Benussi, A., Premi, E., Gazzina, S., Cantoni, V., Cotelli, M. S., Giunta, M., Gasparotti, R., Calhoun, V. D., & Borroni, B. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.05.017 · Cited by 18
Mohammadnejad, A., Soerensen, M., Baumbach, J., Mengel‐From, J., Li, W., Lund, J., Li, S., Christiansen, L., Christensen, K., Hjelmborg, J., et al. (2021) · Aging Cell · doi:10.1111/acel.13293 · Cited by 18
Chen, P., Chen, G., Zhong, S., Chen, F., Ye, T., Gong, J., Tang, G., Pan, Y., Luo, Z., Qi, Z., et al. (2022) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2022.03.023 · Cited by 18
Beta-Amyloid (Aβ1-42) Increases the Expression of NKCC1 in the Mouse Hippocampus
Lam, P., Vinnakota, C., Guzmán, B. C., Newland, J., Peppercorn, K., Tate, W. P., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2022) · Molecules · doi:10.3390/molecules27082440 · Cited by 17
Self-citationCutuli, D., Giacovazzo, G., Decandia, D., & Coccurello, R. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1010169 · Cited by 19
Kuhse, J., Groeneweg, F. L., Kins, S., Gorgas, K., Nawrotzki, R., Kirsch, J., & Kiss, É. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054623 · Cited by 17
Terreros-Roncal, J., Flor-García, M., Moreno-Jiménez, E. P., Pallas-Bazarra, N., Rábano, A., Sah, N., van Praag, H., Giacomini, D., Schinder, A. F., Avila, J., et al. (2019) · Journal of Neuroscience · doi:10.1523/jneurosci.2724-18.2019 · Cited by 15
Vinnakota, C., Govindpani, K., Tate, W. P., Peppercorn, K., Anekal, P. V., Waldvogel, H. J., Faull, R. L. M., & Kwakowsky, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093284 · Cited by 16
Self-citationLithgow, B., Dastgheib, Z. A., Anssari, N., Mansouri, B., Blakley, B. W., Ashiri, M., & Moussavi, Z. (2021) · Medical & Biological Engineering & Computing · doi:10.1007/s11517-021-02409-8 · Cited by 16
Soluble β-amyloid impaired the GABA inhibition by mediating KCC2 in early APP/PS1 mice
Zhou, Y., Cheng, Y., Li, Y., Ma, J., Wu, Z., Chen, Y., Mei, J., & Chen, M. (2021) · BioScience Trends · doi:10.5582/bst.2021.01245 · Cited by 17
Therapeutic potential of alpha 5 subunit containing GABA A receptors in Alzheimer’s disease
Kwakowsky, A., Waldvogel, H. J., & Faull, R. L. M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.300987 · Cited by 15
Self-citationTDP-43 regulates GAD1 mRNA splicing and GABA signaling in Drosophila CNS
Romano, G., Holodkov, N., Klima, R., & Feiguin, F. M. (2021) · Scientific Reports · doi:10.1038/s41598-021-98241-z · Cited by 15
Modifiable risk factors of dementia linked to excitation-inhibition imbalance
Hafizi, S., & Rajji, T. K. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101804 · Cited by 16
Transcriptomic analysis reveals sex-specific patterns in the hippocampus in Alzheimer’s disease
Onisiforou, A., Christodoulou, C. C., Zamba‐Papanicolaou, E., Zanos, P., & Georgiou, P. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1345498 · Cited by 14
Spagnuolo, M. S., Mazzoli, A., Nazzaro, M., Troise, A. D., Gatto, C., Tonini, C., Colardo, M., Segatto, M., Scaloni, A., Pallottini, V., et al. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-03115-8 · Cited by 14
Parvalbumin as a sex-specific target in Alzheimer’s disease research – A mini-review
Terstege, D. J., & Epp, J. R. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105370 · Cited by 14
Carton, L., Auger, F., Kyheng, M., Pétrault, M., Durieux, N., Allorge, D., Cottencin, O., Jardri, R., Bordet, R., & Rolland, B. (2019) · Scientific Reports · doi:10.1038/s41598-019-47187-4 · Cited by 14
Baseline Prediction of rTMS efficacy in Alzheimer patients
Lithgow, B., Dastgheib, Z. A., & Moussavi, Z. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114348 · Cited by 14
Metadata
- Authors
- Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A.
- Affiliations
- University of Auckland (NZ)
- Centre for Brain Research, Department of Anatomy and Medical Imaging, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand
- Corresponding author
- Kwakowsky, Andrea
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2017-08-21
- Volume
- 18
- Issue
- 8
- Pages
- 1813
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC5578199
- OpenAlex
- W2746415584
- Cited by
- 208
- References
- 353
- Citations by year
- 2026: 20 · 2025: 14 · 2024: 25 · 2023: 26 · 2022: 16 · 2021: 41 · 2020: 29 · 2019: 29 · 2018: 5 · 2017: 2
- FWCI
- 2.18
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- ResearchSpace (University of Auckland) (submittedVersion, cc-by)
- Funders
- Aotearoa Foundation (3705579)
- Brain Research New Zealand (3710638)
- Health Research Council of New Zealand (3627373)
- Maurice and Phyllis Paykel Trust (3713650)
- Auckland Medical Research Foundation (3712563)
- University of Otago (110089.01)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, GABAergic system, inhibitory neurotransmission, excitation-inhibition balance, neurodegeneration, AD pathogenesis, therapeutic target
- MeSH terms
- Alzheimer Disease, Brain, gamma-Aminobutyric Acid, Humans, Neurotransmitter Agents, GABAergic Neurons
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
